Lemtrada decision expected in Q4; Discovery Labs nabs $30M loan;

 @FierceBiotech: Sanofi rebuilds early-stage R&D strategy in thriving Boston/Cambridge hub. Story | Follow @FierceBiotech

@JohnCFierce: Gregoire exits Shire HGT one step ahead of new CEO's debut (any chance this is connected to new CEO selection?) Article | Follow @JohnCFierce

@RyanMFierce: Boehringer Ingelheim goes to Hungary for R&D software. Article | Follow @RyanMFierce

> Genzyme CEO David Meeker told an industry group today that he is expecting an FDA decision on the multiple sclerosis treatment Lemtrada in the fourth quarter of 2013. Story

> Discovery Laboratories ($DSCO) says it's lined up a $30 million loan from Deerfield Management. Story

> Citing a downturn in the industry, Huntingdon Life Sciences in the U.K. let go of 95 staffers. Story

> The U.K.'s Domainex has lined up $2.3 million in new venture funding. Story

Pharma News

@FiercePharma: Pharma girds for battle against Medicaid-level rebates for 'dual eligibles.' Fought and won before, but this time? More | Follow @FiercePharma

@EricPFierce: Takeda and one of its contract manufacturers sanctioned by Japanese regulator. Plant ordered closed for 12 days. News | Follow @EricPFierce

@AlisonBFierce: 2012 marked the largest whooping cough outbreak in 50 years. A new vaccine-resistant strain may be to blame. Report | Follow @AlisonBFierce

> Eylea boosts Regeneron past estimates; Actelion hikes dividend for waiting investors. Story

> Merck to pay $688M in lawsuit over failed Vytorin study. Article

> Teva's at-risk Protonix launch could cost $2B-plus. News

Medical Device News

 @FierceMedDev: Special Report: R&D advances in cancer Dx. Special Report | Follow @FierceMedDev

 @MarkHFierce: Medtronic wins with new study that touts merit of DBS for early Parkinson's. More | Follow @MarkHFierce

 @DamianFierce: The medical device tax is particularly treacherous for small companies, Theragenics says. Article | Follow @DamianFierce

> Rigid FX cited for quality violations concerning orthopedic surgical device. Item

> Hospira back in FDA's sights over device manufacturing. Story

Pharma Manufacturing News

> Takeda, CMO hit with sanctions by Japanese regulator. More

> Baxter beefing up cytotoxic manufacturing. Story

> Sanofi again turns to Waterford plant for production solution. Report

> Hospira moves forward with two plants in India. Article

Vaccines News

> Study: Untreated depression decreased effectiveness of shingles vaccine. More

> New whooping cough strain may resist vaccine. Story

> PharmaJet needle-free injector nabs WHO nod. Article

> EMA: Intercell can market Ixiaro in EU. More

> GSK flu vaccine additive under the microscope. Report

And Finally… Officials say an 11th person has been infected with a SARS-like virus, arousing concerns about a potential outbreak. Story

 

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.